Figure. 1. The collagen-associated antitumor pathways.

Figure. 1. The collagen-associated antitumor pathways. (A): Collagen-associated drug delivery and therapeutic targets in the tumor immune microenvironment. (B): The therapeutic targets associated with the collagen-enhancing tumor signaling pathways. TAM: Tumor-associated Macrophage; CBD: collagen binding domain; LOX: lysyl oxidase; TGF-β: transforming growth factor β; NK cell: natural killer cell; CAF: cancer-associated fibroblast; MDSC: myeloid-derived suppressor cell; DC: dendritic cell; DDR: discoidin domain receptor; LAIR-1: leukocyte-associated immunoglobulin-like receptor-1; CCL17: C-C chemokine ligand 17; EMT: epithelial- mesenchymal transition; IFN-γ: interferon-γ. Ras: rat sarcoma; Grb2: growth factor receptorbound protein 2; RAF: Raf protein kinase; MEK: mitogen-activated protein kinase kinase; PI3K: phosphatidylinositol 3-kinase; Akt: protein kinase B; FAK: focal adhesion kinase; Src: Src gene; ERK: extracellular signal-regulated kinase; IKKβ: inhibitory kappa B kinase beta; P65: transcription factor p65 protein‌; CD3: cluster of differentiation 3; CD8: cluster of differentiation 8.